Matthew Strobeck - Jan 23, 2024 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Role
Director
Signature
/s/ David Patience, attorney-in-fact
Stock symbol
AXDX
Transactions as of
Jan 23, 2024
Transactions value $
$0
Form type
4
Date filed
1/25/2024, 04:12 PM
Previous filing
Jan 3, 2024
Next filing
Apr 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXDX Common Stock Purchase +100K +483.51% 121K Jan 23, 2024 By Birchview Fund, LLC F1, F2
holding AXDX Common Stock 203K Jan 23, 2024 Direct
holding AXDX Common Stock 2K Jan 23, 2024 As UGMA Custodian for minor children

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXDX Common Stock Warrants (right to buy) Purchase +100K 100K Jan 23, 2024 Common Stock 100K $1.65 By Birchview Fund, LLC F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities are included within 100,000 units of the issuer (the "Units") purchased by the reporting person for $1.50 per Unit in an underwritten public offering. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.
F2 The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

On July 11, 2023, the issuer effected a reverse stock split of its common stock at a ratio of 1-for-10 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, proportionate adjustments were made to the number of shares of the issuer's common stock underlying its outstanding equity awards, warrants and convertible notes, as well as the exercise or conversion price, as applicable. The amounts reported herein (and to be reported in subsequent reports) have been adjusted to reflect the Reverse Stock Split.